The pathogenic potential of the newly discovered TT virus (TTV) is currently a matter of conjecture. Its presence was investigated in the serum of 660 patients, by polymerase chain reaction. TTV was detected in 50% of 221 patients with unselected pathologies, and no significant differences related to age, sex, or organ disease were noted. TTV was present at a significantly higher rate in hemophiliacs (73%) and at lower rates in patients with cirrhosis (30%) and rheumatoid arthritis (28%). Patients with other liver diseases, systemic lupus erythematosus, or psoriasis or receiving hemodialysis had rates of infection similar to those in unselected patients. TTV-positive patients treated with interferon-a for underlying type C hepatitis showed no appreciable changes of TTV viremia levels. Type 1b was by far the most frequent viral genotype (92%), followed by types 2c (5%) and 1a (3%).
The pathogenic potential of the newly discovered TT virus (TTV) is currently a matter of conjecture. Its presence was investigated in the serum of 660 patients, by polymerase chain reaction. TTV was detected in 50% of 221 patients with unselected pathologies, and no significant differences related to age, sex, or organ disease were noted. TTV was present at a significantly higher rate in hemophiliacs (73%) and at lower rates in patients with cirrhosis (30%) and rheumatoid arthritis (28%). Patients with other liver diseases, systemic lupus erythematosus, or psoriasis or receiving hemodialysis had rates of infection similar to those in unselected patients. TTV-positive patients treated with interferon-a for underlying type C hepatitis showed no appreciable changes of TTV viremia levels. Type 1b was by far the most frequent viral genotype (92%), followed by types 2c (5%) and 1a (3%).
TT virus (TTV) is a newly discovered virus of humans that shares a number of genetic characteristics with parvoviruses [1, 2] and circoviruses [3] . Epidemiology and clinical implications are still poorly understood. Circulating viral DNA has been detected in healthy individuals at rates ranging from 1% to 92%, as a possible result of uneven geographic distribution [4, 5] and/or of differences in the sensitivity of the polymerase chain reaction (PCR) methods used for detection [5] . Reports of increased prevalence in persons treated with blood or blood products have suggested parenteral transmission as a frequent route of infection [6] , but other routes appear likely [7] . Since TTV has been detected in patients with cryptogenetic fulminant or chronic hepatitis, a possible involvement in liver pathology has been proposed [1, 2] . However, there are also suggestions that TTV might be apathogenic [8] .
We have tested for circulating TTV in 660 Italian patients. Overall positivity was 50%, and infection was as prevalent in children aged !4 years as in older subjects, thus indicating that TTV is extremely widespread in Italy. No evidence was obtained that suggests the virus might be involved in any of several pathologies considered. TTV viremia was unaltered by inter-
Patients and Methods
Patients. A total of 660 patients living in Tuscany and surrounding areas were studied. The first group consisted of 221 unselected patients (125 male and 96 female), of different ages and with different clinical diagnoses, whose sera had been submitted to our laboratory for routine virological analysis. The other 439 patients were chosen on the basis of specific clinical diagnoses (table  1) . Serum samples had been obtained 1 week to 5 years prior to TTV testing and kept sterile at either Ϫ20ЊC or Ϫ80ЊC.
PCR. A domain of the open reading frame 1 (ORF1) spanning nucleotides 1915-2185 of the TTV isolate TA278 [2] was amplified by means of nested highly conserved primers. In brief, viral DNA was extracted and amplified for 35 cycles with primers A5430 genomes per milliliter was calculated according to the Reed and Muench method.
Genotyping by restriction fragment length polymorphism (RFLP) analysis. The method used was recently developed by Tanaka et al. [9] . In brief, 10 mL of the second PCR products obtained as described above were digested for у3 h at 37ЊC in the presence of 10 U each of NdeI and PstI, followed by cleavage with NlaIII and MseI. Finally, digestion products were analyzed by electrophoresis on 4% Metaphor agarose gel (FMC, Bioproducts, Rockland, ME) and were stained with ethidium bromide.
Genotyping by sequencing. The region sequenced was a 222-bp segment (nucleotides 1939-2160) known to be valuable for TTV genotyping [2, 6] . Some isolates were also characterized by furthering the analysis to 586 bp (nucleotides 1939-2524). In the latter case, the amplification products were obtained with the sense primers described above (A5430 and A8761 for the first and the second steps, respectively) and the antisense primers 16OR (5 -CGGCCTGCTGAAAAAAATTC-3 ; position 2551-2570) and 16IR (5 -GCAGTTGGTTGTTGTTGCATTC-3 ; position 2525-2546). Sequencing was carried out with an automatic DNA sequencer (Amersham Pharmacia Biotech, Uppsala, Sweden).
Phylogenetic analysis. We created multiple alignments, using CLUSTAL V and pairwise evolutionary distances estimated by means of the DNADIST program, by Kimura's two-parameter method. Phylogenetic relationships were computed from these distances by the Neighbor-Joining algorithm and by assessment of the robustness of the branching orders with 100 bootstrap replications and by the DNA parsimony method of PHYLIP software package version 3.5c (J. Felsestein, Seattle, University of Washington).
Results
Prevalence of TTV viremia in unselected patients. Circulating TTV was detected in 110 of the 221 unselected patients tested (table 1) . No statistically significant differences were noted when the patients were grouped by age, sex, or diseased organ (data not shown). Twelve of 19 children aged !4 years were positive for TTV: 6 presented with respiratory distress, 3 with diarrhea, 2 with acute leukemia, and 1 with alopecia.
Prevalence of TTV viremia in patients with selected pathologies. Table 1 also shows the results of testing groups of patients affected by specific diseases. Hemophiliacs had a positivity rate significantly higher than that of unselected patients. Hemodialysis patients had a positivity rate (53%) similar to that of unselected patients. There were no statistical differences in TTV prevalence among liver patients versus unselected patients, except for those with cirrhosis, among whom the prevalence was significantly lower. Also, in the patients with systemic lupus erythematosus (SLE) and psoriasis, the proportion of TTV viremic patients was similar to that in unselected patients. On the other hand, TTV viremia prevalence was only 28% in the rheumatoid arthritis (RA) patients ( ). Among P ! .05 the 370 individuals of the liver and cryptogenetic disease groups, 20 had a known history of blood transfusions or intravenous drug use. Of these, 11 (55%) were TTV positive.
Sensitivity to interferon-a treatment. Of the 123 HCV-positive patients examined, 52 had been treated with IFN-a. TTV viremia prevalence was 42% in these patients, versus 52% in been submitted to GenBank (accession numbers AJ244117-AJ244226). Reference sequences are isolates N22 (AB017767), TA278 (AB008394), TS003 (AB017770), NA004 (AB017771), TX011 (AB011493), TY96117 (AB0114949), G97801 (AB011486), G88801 (AB011491), G105001 (AB011490), G104901 (AB011489), G103301 (AB011487), G102001 (AB011488), PT3 (AB017768), strain JaCHC19 isolate TC19 (AB018858), clone JaM59 (AB017891), strain JaNBNC10 isolate CK7 (AB018961), clone JaM18 (AB017886), clone JaM21 (AB017887), and clone JaM28 (AB017888) from Japan; isolate BT/3 (AF060547) from Germany; isolates from blood donors 13 (AF079542) and 20 (AF079541) from United Kingdom; and strain TTVCHN1 (AF079173) from China. untreated individuals. We also tested paired pre-and posttreatment sera from 10 doubly infected patients (6 million units 3ϫ/ week for 24 weeks). At the end of treatment, all patients were still TTV viremia positive. Furthermore, in 3 such patients, we quantitated TTV and HCV viremia at selected time points by using limiting dilution PCR and branched DNA (Quantiplex HCV 2.0, Chiron, Emeryville, CA), respectively. The treatment produced a marked albeit transient reduction of circulating HCV in 2 patients but had no effect on TTV levels, which ranged from 10 3.5 to 10 5 amplifiable genomes per milliliter throughout the 9-month observation period (data not shown).
Genotyping and phylogenetic analysis of TTV isolates. Using RFLP analysis, we characterized 157 TTV isolates randomly selected from our 330 positive patients. With one exception, all the isolates felt into known genotypes: 148 into genotype 1 and the remaining 8 into genotypes 2-6. Many such isolates (101 of type 1 and the 9 not belonging to this type 1) were also characterized by sequence analysis. Only 4 were found not to have been correctly typed by RFLP analysis.
Sequence analysis also permits definition of genetic subtypes and phylogenetic relationships of novel isolates to previously published strains. As shown by figure 1A, 92% of our isolates (including the 1 that had remained unclassified by RFLP analysis) were characterized as subtype 1b, 5% as 2c, and 3% as 1a. Whereas subtype 1a and 1b isolates clustered tightly-and this was true with both algorithms used-type 2 isolates clustered into 2 major branches, one encompassing the sequences representative of subtypes 2a and 2b and the other encompassing the 2 published sequences representative of subtype 2c and all of our type 2 isolates. It should be noted, however, that the low bootstrap and statistical significance values make assignments to subtypes within genotype 2 rather weak. Of interest, clustering of the isolates was independent of patient's disease or age. We confirmed this latter finding by extending to 586 bp the sequence analysis of 48 genotype 1 isolates (figure 1B).
Discussion
Reported TTV carrier rates in the general population range ∼1%-10% in the United Kingdom [6, 8] and United States [4] , 5% in France [10] , 7%-36% in Thailand [11, 12] , and 12% in Japan [2] . Evidence also suggests that the PCR method used may greatly affect the results of prevalence studies. For example, using improved primers, Takahashi et al. [5] recently reported that TTV carriers among healthy Japanese can be as many as 92%. Although more-standardized detection methods are needed to establish the true prevalence worldwide, here we have focused on sick individuals in an attempt to find clues to the pathogenic role of TTV. To date, no pathology has been firmly associated with TTV. Suggestions that the virus might cause some forms of acute non-A-non-G hepatitis [1] have been questioned [8] .
TTV viremia prevalence in our 221 unselected patients was 50%. Given the wide spectrum of diseases and ages represented in this group, we can infer that the diffusion of TTV viremia in Italy is most likely much higher than the diffusion reported for the United Kingdom and the United States. The fact that our primers were a combination of those used by Okamoto et al. [2] and by Simmonds et al. [6] might, however, have contributed to the high prevalence rate detected. No indications were found in these patients that viremia was especially frequent among individuals with a specific diseased organ or belonging to a given sex or age group. However, the observation that 63% of children aged !4 years were viremic suggests that acquisition of infection early in life is frequent.
The other groups of patients tested were selected on the basis of either previous data indicating that they might have a higher frequency of TTV infection (patients at risk for parenteral infection) or the suspected viral nature of their diseases (SLE, psoriasis, RA). Carriers were more frequent among hemophiliacs who had received concentrates not subjected to virucidal treatments than among unselected patients, thus confirming that untreated blood products used to be a frequent vehicle of TTV infection [6] . In contrast, hemodialysis did not appear to add to the risk of contracting the infection, at least in areas of high endemia such as ours. Overall, the patients with liver pathologies also displayed TTV viremia prevalence rates similar to those in unselected patients. Of interest, HCV-infected patients exhibited similar prevalence rates regardless of whether they had previously been treated with IFN-a, thus suggesting that TTV is resistant to such treatment. This conclusion was fully borne out by studies in which we measured the levels of circulating TTV in 3 patients prior to, during, and after IFNa treatment.
Although it is generally believed that SLE, psoriasis, and RA result from the combined action of genetic and environmental factors, their etiopathogenesis is unresolved. Attempts to implicate a variety of viruses have been inconclusive [13, 14] . That TTV viremia prevalence in these diseases was in the same range as or lower than prevalence in unselected patients suggests that TTV does not represent an important trigger for their development. The finding that patients with cirrhosis and RA had reduced levels of TTV positivity will require further investigation in larger groups of patients. We used a recently described RFLP assay [9] to genotype 157 of our isolates. As determined by subsequent sequence analysis of 110 such isolates, the assay assigned 96% of the isolates to the correct genotype, thus confirming its reliability. Sequence analysis also showed that the great majority of our isolates belonged to subtype 1b (92%) and that the remaining were either type 1a or type 2c. When compared with previous data [2, 6] , this indicates that the distribution of TTV genotypes in Italy differs from that in other countries, thus duplicating what was already seen with HCV [15] . We also performed a phylogenetic analysis of the isolates and found no evidence that they clustered differently depending on patient's age or other variables.
In conclusion, the high frequency of virus carriers detected in this and previous studies indicates that chronic TTV infection is essentially harmless. Since we have shown that TTV infection is acquired early in life, especially in situations of high endemia, and that recognizing pathologies produced in a fraction of infected individuals can be extremely difficult, further investigations should focus on infants, to identify primary infections and possible associated diseases.
